Cumulative meta-analysis

mRS 0 to 2



mRS 0 to 1



**Supplementary Figure 8.** Cumulative meta-analyses and leave-one-out influence analyses. mRS, modified Rankin Scale; RR, risk ratio; CI, confidence interval; TNK, tenecteplase; ALT, alteplase.

Complete recanalization

| Study | Complete Recanalization | RR | 95%-CI | P-value | Tau2 | Tau | I2 |
|---|---|---|---|---|---|---|---|
| Adding Parsons et al. Neurology. 2009. (k=1) | | 3.33 | [1.57; 7.08] | < 0.01 | . | . | . |
| Adding Parsons et al. N Engl J Med. 2012. (0.1 mg/kg) (k=2) | | 2.27 | [0.04; 126.59] | 0.23 | < 0.0001 | 0.0020 | 40% |
| Adding Huang et al. Lancet Neurol. 2015. (k=3) | | 1.58 | [0.28; 8.74] | 0.37 | 0.2281 | 0.4776 | 82% |
| Adding Campbell et al. N Engl J Med. 2018. (k=4) | | 1.56 | [0.62; 3.89] | 0.22 | 0.1615 | 0.4018 | 74% |
| Adding Sundar et al. Neurol Asia. 2019. (k=5) | | 1.61 | [0.79; 3.30] | 0.14 | 0.1615 | 0.4019 | 67% |
| Adding George et al. J Clin Neurosci. 2021. (k=6) | | 1.51 | [0.70; 3.26] | 0.23 | 0.1650 | 0.4063 | 67% |
| Adding Psychogios et al. Thera Adv Neurol Disord. 2021. (k=7) | | 1.53 | [0.83; 2.83] | 0.14 | 0.1347 | 0.3670 | 61% |
| Adding Bivard et al. Lancet Neurol. 2022. (k=8) | | 1.37 | [0.83; 2.27] | 0.18 | 0.1182 | 0.3438 | 60% |
| Adding Gerschenfeld et al. Eur Stroke J. 2022. (k=9) | | 1.25 | [0.82; 1.90] | 0.26 | 0.1000 | 0.3163 | 61% |
| Adding Hendrix et al. J Neurointerv Surg. 2022. (k=10) | | 1.33 | [0.89; 1.99] | 0.14 | 0.1194 | 0.3455 | 63% |
| Adding Menon et al. Lancet. 2022. (k=11) | | 1.28 | [0.91; 1.80] | 0.13 | 0.0871 | 0.2951 | 59% |
| Adding Checkouri et al. Eur Stroke J. 2023. (k=12) | | 1.18 | [0.76; 1.82] | 0.42 | 0.2493 | 0.4993 | 75% |
| Adding Mohan et al. Ann Indian Acad Neurol. 2023. (k=13) | | 1.14 | [0.74; 1.76] | 0.52 | 0.2517 | 0.5017 | 74% |
| Adding Walton et al. Ann Pharmacother. 2023. (k=14) | | 1.08 | [0.72; 1.62] | 0.69 | 0.2492 | 0.4992 | 73% |
| Adding Zhao et al. Front Neurol. 2023. (k=15) | | 1.15 | [0.78; 1.69] | 0.46 | 0.2668 | 0.5165 | 78% |
| Random effects model | | 1.15 | [0.78; 1.69] | 0.46 | 0.2668 | 0.5165 | 78% |

0.1  0.2  0.5  1  2  5  10
Higher in ALT  Higher in TNK

Mortality

| Study | Mortality | RR | 95%-CI | P-value | Tau2 | Tau | I2 |
|---|---|---|---|---|---|---|---|
| Adding Haley et al. Stroke. 2010. (0.1mg/kg) (k=1) | | 0.25 | [0.06; 1.08] | 0.06 | . | . | . |
| Adding Haley et al. Stroke. 2010. (0.25mg/kg) (k=2) | | 0.63 | [0.00; 712.16] | 0.55 | < 0.0001 | 0.0004 | 51% |
| Adding Haley et al. Stroke. 2010. (0.4mg/kg) (k=3) | | 0.62 | [0.15; 2.59] | 0.29 | < 0.0001 | 0.0024 | 3% |
| Adding Parsons et al. N Engl J Med. 2012. (0.1 mg/kg) (k=4) | | 0.63 | [0.29; 1.38] | 0.16 | 0 | 0 | 0% |
| Adding Huang et al. Lancet Neurol. 2015. (k=5) | | 0.77 | [0.38; 1.56] | 0.37 | < 0.0001 | 0.0006 | 0% |
| Adding Logallo et al. Lancet Neurol. 2017. (k=6) | | 0.93 | [0.58; 1.48] | 0.69 | < 0.0001 | 0.0022 | 0% |
| Adding Campbell et al. N Engl J Med. 2018. (k=7) | | 0.84 | [0.55; 1.27] | 0.34 | < 0.0001 | 0.0009 | 7% |
| Adding George et al. J Clin Neurosci. 2021. (k=8) | | 0.81 | [0.54; 1.22] | 0.26 | 0.0046 | 0.0680 | 7% |
| Adding Mahawish et al. Stroke. 2021. (k=9) | | 0.77 | [0.56; 1.05] | 0.09 | 0 | 0 | 1% |
| Adding Psychogios et al. Thera Adv Neurol Disord. 2021. (k=10) | | 0.76 | [0.57; 1.01] | 0.06 | 0 | 0 | 0% |
| Adding Zhong et al. Stroke. 2021. (k=11) | | 0.84 | [0.63; 1.11] | 0.20 | 0.0236 | 0.1536 | 12% |
| Adding Bivard et al. Lancet Neurol. 2022. (k=12) | | 0.84 | [0.65; 1.09] | 0.18 | 0.0191 | 0.1382 | 4% |
| Adding Dhar et al. Ann Indian Acad Neurol. 2022. (k=13) | | 0.88 | [0.67; 1.15] | 0.31 | 0.0199 | 0.1411 | 13% |
| Adding Estella et al. J Pers Med. 2022. (k=14) | | 0.89 | [0.69; 1.14] | 0.34 | 0.0148 | 0.1215 | 8% |
| Adding Gerschenfeld et al. Eur Stroke J. 2022. (k=15) | | 0.86 | [0.70; 1.06] | 0.14 | 0.0036 | 0.0596 | 5% |
| Adding Kvistad et al. Lancet Neurol. 2022. (k=16) | | 0.91 | [0.70; 1.17] | 0.44 | 0.0301 | 0.1735 | 31% |
| Adding Li et al. Stroke Vasc Neurol. 2022. (0.1mg/kg) (k=17) | | 0.91 | [0.72; 1.16] | 0.42 | 0.0251 | 0.1584 | 26% |
| Adding Li et al. Stroke Vasc Neurol. 2022. (0.25mg/kg) (k=18) | | 0.90 | [0.70; 1.15] | 0.36 | 0.0261 | 0.1614 | 29% |
| Adding Li et al. Stroke Vasc Neurol. 2022. (0.32mg/kg) (k=19) | | 0.89 | [0.71; 1.13] | 0.32 | 0.0217 | 0.1472 | 25% |
| Adding Menon et al. Lancet. 2022. (k=20) | | 0.93 | [0.78; 1.10] | 0.35 | < 0.0001 | 0.0017 | 23% |
| Adding Tsivgoulis et al. Ann Neurol. 2022. (k=21) | | 0.85 | [0.67; 1.07] | 0.15 | 0.0732 | 0.2705 | 44% |
| Adding Warach et al. Stroke. 2022. (k=22) | | 0.83 | [0.66; 1.03] | 0.09 | 0.0688 | 0.2623 | 44% |
| Adding Chandra et al. Arch Med Health Sci. 2023. (k=23) | | 0.84 | [0.68; 1.05] | 0.12 | 0.0705 | 0.2655 | 43% |
| Adding Mohan et al. Ann Indian Acad Neurol. 2023. (k=24) | | 0.83 | [0.67; 1.03] | 0.09 | 0.0697 | 0.2639 | 42% |
| Adding Murphy et al. Ann Emerg Med. 2023. (k=25) | | 0.83 | [0.69; 1.01] | 0.06 | 0.0483 | 0.2199 | 40% |
| Adding Qureshi et al. J Stroke Cerebrovasc Dis. 2023. (No Thrombectomy) (k=26) | | 0.86 | [0.72; 1.03] | 0.10 | 0.0561 | 0.2368 | 45% |
| Adding Qureshi et al. J Stroke Cerebrovasc Dis. 2023. (Thrombectomy) (k=27) | | 0.87 | [0.74; 1.04] | 0.12 | 0.0493 | 0.2220 | 44% |
| Adding Sjogren et al. IBRO Neurosci Rep. 2023. (k=28) | | 0.90 | [0.75; 1.08] | 0.24 | 0.0649 | 0.2547 | 48% |
| Adding Walton et al. Ann Pharmacother. 2023. (k=29) | | 0.90 | [0.76; 1.07] | 0.23 | 0.0620 | 0.2490 | 46% |
| Adding Wang et al. Lancet. 2023. (k=30) | | 0.92 | [0.78; 1.09] | 0.33 | 0.0632 | 0.2513 | 47% |
| Adding Warach et al. JAMA Neurol. 2023. (k=31) | | 0.95 | [0.81; 1.12] | 0.53 | 0.0724 | 0.2691 | 61% |
| Adding Zhao et al. Front Neurol. 2023. (k=32) | | 0.96 | [0.81; 1.13] | 0.61 | 0.0723 | 0.2688 | 60% |
| Random effects model | | 0.96 | [0.81; 1.13] | 0.61 | 0.0723 | 0.2688 | 60% |

0.1  0.2  0.5  1  2  5  10
Higher in ALT  Higher in TNK

**Supplementary Figure 8.** Cumulative meta-analyses and leave-one-out influence analyses. RR, risk ratio; CI, confidence interval; TNK, tenecteplase; ALT, alteplase.

JoS

Koh et al.    Tenecteplase Versus Alteplase in Acute Ischemic Stroke

sICH

| Study | sICH | RR | 95%-CI | P-value | Tau2 | Tau | I2 |
|---|---|---|---|---|---|---|---|
| Adding Haley et al. Stroke. 2010. (0.1mg/kg) (k=1) | | 0.33 | [0.01; 7.87] | 0.50 | . | . | . |
| Adding Haley et al. Stroke. 2010. (0.25mg/kg) (k=2) | | 1.06 | [0.00; 57145.11] | 0.96 | 0 | 0 | 0% |
| Adding Haley et al. Stroke. 2010. (0.4mg/kg) (k=3) | | 2.03 | [0.10; 42.30] | 0.42 | < 0.0001 | 0.0002 | 0% |
| Adding Parsons et al. N Engl J Med. 2012. (0.1 mg/kg) (k=4) | | 1.01 | [0.12; 8.70] | 0.99 | 0.2534 | 0.5034 | 31% |
| Adding Huang et al. Lancet Neurol. 2015. (k=5) | | 0.90 | [0.24; 3.31] | 0.83 | < 0.0001 | 0.0005 | 10% |
| Adding Logallo et al. Lancet Neurol. 2017. (k=6) | | 1.04 | [0.51; 2.12] | 0.89 | 0 | 0 | 0% |
| Adding Campbell et al. N Engl J Med. 2018. (k=7) | | 1.04 | [0.57; 1.90] | 0.88 | 0 | 0 | 0% |
| Adding Sundar et al. Neurol Asia. 2019. (k=8) | | 1.02 | [0.61; 1.69] | 0.93 | 0 | 0 | 0% |
| Adding George et al. J Clin Neurosci. 2021. (k=9) | | 0.92 | [0.58; 1.45] | 0.68 | 0 | 0 | 0% |
| Adding Hall et al. Stroke. 2021. (k=10) | | 0.87 | [0.56; 1.37] | 0.51 | 0 | 0 | 0% |
| Adding Mahawish et al. Stroke. 2021. (k=11) | | 0.79 | [0.53; 1.19] | 0.24 | 0 | 0 | 0% |
| Adding Psychogios et al. Thera Adv Neurol Disord. 2021. (k=12) | | 0.86 | [0.56; 1.31] | 0.44 | 0 | 0 | 0% |
| Adding Zhong et al. Stroke. 2021. (k=13) | | 0.84 | [0.57; 1.24] | 0.34 | 0 | 0 | 0% |
| Adding Bivard et al. Lancet Neurol. 2022. (k=14) | | 0.84 | [0.57; 1.24] | 0.34 | 0 | 0 | 0% |
| Adding Dhar et al. Ann Indian Acad Neurol. 2022. (k=15) | | 0.87 | [0.59; 1.29] | 0.45 | 0 | 0 | 0% |
| Adding Estella et al. J Pers Med. 2022. (k=16) | | 0.99 | [0.67; 1.47] | 0.97 | 0.0197 | 0.1403 | 3% |
| Adding Gerschenfeld et al. Eur Stroke J. 2022. (k=17) | | 0.94 | [0.66; 1.33] | 0.70 | 0.0104 | 0.1019 | 2% |
| Adding Hendrix et al. J Neurointerv Surg. 2022. (k=18) | | 0.96 | [0.68; 1.37] | 0.82 | 0.0110 | 0.1051 | 3% |
| Adding Kvistad et al. Lancet Neurol. 2022. (k=19) | | 1.01 | [0.70; 1.46] | 0.97 | 0.0269 | 0.1640 | 13% |
| Adding Li et al. Stroke Vasc Neurol. 2022. (0.1mg/kg) (k=20) | | 1.03 | [0.72; 1.48] | 0.87 | 0.0281 | 0.1677 | 12% |
| Adding Li et al. Stroke Vasc Neurol. 2022. (0.25mg/kg) (k=21) | | 1.02 | [0.72; 1.45] | 0.92 | 0.0250 | 0.1580 | 9% |
| Adding Li et al. Stroke Vasc Neurol. 2022. (0.32mg/kg) (k=22) | | 1.03 | [0.73; 1.45] | 0.86 | 0.0219 | 0.1481 | 6% |
| Adding Menon et al. Lancet. 2022. (k=23) | | 1.04 | [0.78; 1.38] | 0.79 | 0 | 0 | 1% |
| Adding Tsivgoulis et al. Ann Neurol. 2022. (k=24) | | 1.02 | [0.78; 1.34] | 0.87 | 0 | 0 | 0% |
| Adding Warach et al. Stroke. 2022. (k=25) | | 1.00 | [0.77; 1.30] | 0.98 | 0 | 0 | 0% |
| Adding Chandra et al. Arch Med Health Sci. 2023. (k=26) | | 0.99 | [0.76; 1.28] | 0.93 | 0 | 0 | 0% |
| Adding Mohan et al. Ann Indian Acad Neurol. 2023. (k=27) | | 0.98 | [0.76; 1.27] | 0.86 | 0 | 0 | 0% |
| Adding Sjogren et al. IBRO Neurosci Rep. 2023. (k=28) | | 1.01 | [0.78; 1.31] | 0.94 | 0 | 0 | 0% |
| Adding Walton et al. Ann Pharmacother. 2023. (k=29) | | 1.00 | [0.77; 1.29] | 0.99 | 0 | 0 | 0% |
| Adding Wang et al. Lancet. 2023. (k=30) | | 1.02 | [0.82; 1.28] | 0.83 | 0 | 0 | 0% |
| Adding Warach et al. JAMA Neurol. 2023. (k=31) | | 0.92 | [0.72; 1.18] | 0.51 | 0.0867 | 0.2944 | 24% |
| Adding Zhao et al. Front Neurol. 2023. (k=32) | | 0.93 | [0.73; 1.19] | 0.56 | 0.0871 | 0.2951 | 23% |
| **Random effects model** | | **0.93** | **[0.73; 1.19]** | **0.56** | **0.0871** | **0.2951** | **23%** |

```
0.1   0.2   0.5   1   2   5   10
     Higher in ALT   Higher in TNK
```

Any ICH

| Study | Any ICH | RR | 95%-CI | P-value | Tau2 | Tau | I2 |
|---|---|---|---|---|---|---|---|
| Adding Haley et al. Stroke. 2010. (0.1mg/kg) (k=1) | | 0.60 | [0.16; 2.30] | 0.46 | . | . | . |
| Adding Haley et al. Stroke. 2010. (0.25mg/kg) (k=2) | | 0.70 | [0.11; 4.33] | 0.25 | 0 | 0 | 0% |
| Adding Haley et al. Stroke. 2010. (0.4mg/kg) (k=3) | | 0.99 | [0.27; 3.62] | 0.97 | 0 | 0 | 0% |
| Adding Huang et al. Lancet Neurol. 2015. (k=4) | | 0.79 | [0.37; 1.65] | 0.38 | 0 | 0 | 0% |
| Adding Logallo et al. Lancet Neurol. 2017. (k=5) | | 0.88 | [0.62; 1.26] | 0.39 | 0 | 0 | 0% |
| Adding Sundar et al. Neurol Asia. 2019. (k=6) | | 0.86 | [0.63; 1.17] | 0.26 | 0 | 0 | 0% |
| Adding George et al. J Clin Neurosci. 2021. (k=7) | | 0.82 | [0.61; 1.09] | 0.14 | 0 | 0 | 0% |
| Adding Hall et al. Stroke. 2021. (k=8) | | 0.80 | [0.64; 1.02] | 0.07 | 0 | 0 | 0% |
| Adding Psychogios et al. Thera Adv Neurol Disord. 2021. (k=9) | | 0.84 | [0.64; 1.10] | 0.17 | < 0.0001 | 0.0015 | 0% |
| Adding Dhar et al. Ann Indian Acad Neurol. 2022. (k=10) | | 0.88 | [0.66; 1.18] | 0.34 | < 0.0001 | 0.0007 | 10% |
| Adding Kvistad et al. Lancet Neurol. 2022. (k=11) | | 1.02 | [0.67; 1.56] | 0.92 | 0.1430 | 0.3781 | 48% |
| Adding Li et al. Stroke Vasc Neurol. 2022. (0.1mg/kg) (k=12) | | 1.06 | [0.71; 1.60] | 0.74 | 0.1498 | 0.3870 | 47% |
| Adding Li et al. Stroke Vasc Neurol. 2022. (0.25mg/kg) (k=13) | | 1.06 | [0.73; 1.55] | 0.74 | 0.1348 | 0.3672 | 42% |
| Adding Li et al. Stroke Vasc Neurol. 2022. (0.32mg/kg) (k=14) | | 1.10 | [0.76; 1.59] | 0.58 | 0.1404 | 0.3747 | 42% |
| Adding Menon et al. Lancet. 2022. (k=15) | | 0.98 | [0.80; 1.20] | 0.81 | 0 | 0 | 38% |
| Adding Mohan et al. Ann Indian Acad Neurol. 2023. (k=16) | | 0.97 | [0.79; 1.18] | 0.71 | < 0.0001 | 0.0016 | 38% |
| Adding Murphy et al. Ann Emerg Med. 2023. (k=17) | | 1.01 | [0.85; 1.20] | 0.90 | < 0.0001 | 0.0010 | 37% |
| Adding Sjogren et al. IBRO Neurosci Rep. 2023. (k=18) | | 1.02 | [0.86; 1.20] | 0.80 | < 0.0001 | 0.0019 | 35% |
| Adding Walton et al. Ann Pharmacother. 2023. (k=19) | | 1.02 | [0.88; 1.20] | 0.75 | < 0.0001 | 0.0018 | 31% |
| Adding Wang et al. Lancet. 2023. (k=20) | | 1.01 | [0.87; 1.17] | 0.88 | < 0.0001 | 0.0019 | 29% |
| Adding Zhao et al. Front Neurol. 2023. (k=21) | | 1.02 | [0.88; 1.19] | 0.74 | < 0.0001 | 0.0012 | 32% |
| **Random effects model** | | **1.02** | **[0.88; 1.19]** | **0.74** | **< 0.0001** | **0.0012** | **32%** |

```
0.1   0.2   0.5   1   2   5   10
     Higher in ALT   Higher in TNK
```

**Supplementary Figure 8.** Cumulative meta-analyses and leave-one-out influence analyses. sICH, symptomatic intracranial hemorrhage; ICH, intracranial hemorrhage; RR, risk ratio; CI, confidence interval; TNK, tenecteplase; ALT, alteplase.

Early neurological improvement

| Study | Early Neurological Improvement | RR | 95%-CI | P-value | Tau2 | Tau | I2 |
|---|---|---|---|---|---|---|---|
| Adding Parsons et al. Neurology. 2009. (k=1) | | 3.33 | [1.57; 7.08] | < 0.01 | . | . | . |
| Adding Haley et al. Stroke. 2010. (0.1mg/kg) (k=2) | | 2.47 | [0.01; 468.12] | 0.27 | < 0.0001 | 0.0022 | 43% |
| Adding Haley et al. Stroke. 2010. (0.25mg/kg) (k=3) | | 2.38 | [0.82; 6.91] | 0.07 | 0 | 0 | 0% |
| Adding Haley et al. Stroke. 2010. (0.4mg/kg) (k=4) | | 2.17 | [1.06; 4.43] | 0.04 | 0 | 0 | 0% |
| Adding Parsons et al. N Engl J Med. 2012. (0.1 mg/kg) (k=5) | | 2.00 | [1.29; 3.09] | 0.01 | 0 | 0 | 0% |
| Adding Huang et al. Lancet Neurol. 2015. (k=6) | | 1.90 | [1.37; 2.63] | < 0.01 | 0 | 0 | 0% |
| Adding Logallo et al. Lancet Neurol. 2017. (k=7) | | 1.57 | [1.09; 2.25] | 0.02 | 0.0712 | 0.2668 | 57% |
| Adding Campbell et al. N Engl J Med. 2018. (k=8) | | 1.14 | [0.94; 1.37] | 0.15 | 0 | 0 | 54% |
| Adding Psychogios et al. Thera Adv Neurol Disord. 2021. (k=9) | | 1.46 | [1.10; 1.94] | 0.02 | 0.0671 | 0.2590 | 57% |
| Adding Kvistad et al. Lancet Neurol. 2022. (k=10) | | 1.36 | [1.00; 1.84] | 0.05 | 0.1036 | 0.3218 | 69% |
| Adding Chandra et al. Arch Med Health Sci. 2023. (k=11) | | 1.39 | [1.05; 1.83] | 0.02 | 0.0994 | 0.3152 | 69% |
| Adding Mohan et al. Ann Indian Acad Neurol. 2023. (k=12) | | 1.33 | [1.02; 1.72] | 0.04 | 0.0930 | 0.3049 | 67% |
| Adding Wang et al. Lancet. 2023. (k=13) | | 1.26 | [1.00; 1.60] | 0.05 | 0.0801 | 0.2831 | 66% |
| Adding Zhao et al. Front Neurol. 2023. (k=14) | | 1.32 | [1.03; 1.68] | 0.03 | 0.0951 | 0.3083 | 67% |
| Random effects model | | 1.32 | [1.03; 1.68] | 0.03 | 0.0951 | 0.3083 | 67% |

0.1 0.2 0.5 1 2 5 10
Higher in ALT    Higher in TNK

Parenchymal hemorrhage

| Study | Parenchymal Hemorrhage | RR | 95%-CI | P-value | Tau2 | Tau | I2 |
|---|---|---|---|---|---|---|---|
| Adding Parsons et al. Neurology. 2009. (k=1) | | 0.25 | [0.01; 4.44] | 0.35 | . | . | . |
| Adding Parsons et al. N Engl J Med. 2012. (0.1 mg/kg) (k=2) | | 0.67 | [0.00; 224.90] | 0.54 | 0 | 0 | 0% |
| Adding Huang et al. Lancet Neurol. 2015. (k=3) | | 0.50 | [0.07; 3.55] | 0.27 | 0 | 0 | 0% |
| Adding Campbell et al. N Engl J Med. 2018. (k=4) | | 0.75 | [0.23; 2.43] | 0.49 | 0 | 0 | 0% |
| Adding Hall et al. Stroke. 2021. (k=5) | | 0.63 | [0.25; 1.58] | 0.23 | 0 | 0 | 0% |
| Adding Bivard et al. Lancet Neurol. 2022. (k=6) | | 0.63 | [0.25; 1.58] | 0.23 | 0 | 0 | 0% |
| Adding Gerschenfeld et al. Eur Stroke J. 2022. (k=7) | | 0.64 | [0.43; 0.96] | 0.04 | 0 | 0 | 0% |
| Adding Hendrix et al. J Neurointerv Surg. 2022. (k=8) | | 0.65 | [0.46; 0.92] | 0.02 | 0 | 0 | 0% |
| Adding Kvistad et al. Lancet Neurol. 2022. (k=9) | | 0.74 | [0.42; 1.31] | 0.25 | 0 | 0 | 47% |
| Adding Menon et al. Lancet. 2022. (k=10) | | 0.88 | [0.53; 1.46] | 0.58 | 0.0496 | 0.2227 | 48% |
| Adding Sjogren et al. IBRO Neurosci Rep. 2023. (k=11) | | 0.90 | [0.60; 1.36] | 0.59 | 0.0293 | 0.1711 | 43% |
| Adding Wang et al. Lancet. 2023. (k=12) | | 0.97 | [0.61; 1.53] | 0.88 | 0.0609 | 0.2467 | 49% |
| Random effects model | | 0.97 | [0.61; 1.53] | 0.88 | 0.0609 | 0.2467 | 49% |

0.1 0.2 0.5 1 2 5 10
Higher in ALT    Higher in TNK

**Supplementary Figure 8.** Cumulative meta-analyses and leave-one-out influence analyses. RR, risk ratio; CI, confidence interval; TNK, tenecteplase; ALT, alteplase.

Leave-one-out analysis

mRS 0 to 2

| Study | mRS 0 to 2 | RR | 95%-CI | P-value | Tau2 | Tau | I2 |
|---|---|---|---|---|---|---|---|
| Omitting Chandra et al. Arch Med Health Sci. 2023. | | 1.09 | [0.99; 1.20] | 0.08 | 0.0099 | 0.0996 | 66% |
| Omitting Mohan et al. Ann Indian Acad Neurol. 2023. | | 1.09 | [1.00; 1.19] | 0.05 | 0.0080 | 0.0894 | 64% |
| Omitting Wang et al. Lancet. 2023. | | 1.09 | [0.98; 1.21] | 0.10 | 0.0125 | 0.1119 | 64% |
| Omitting Warach et al. JAMA Neurol. 2023. | | 1.07 | [0.97; 1.19] | 0.16 | 0.0113 | 0.1062 | 62% |
| Omitting Zhao et al. Front Neurol. 2023. | | 1.07 | [0.99; 1.17] | 0.10 | 0.0082 | 0.0907 | 62% |
| Omitting Bivard et al. Lancet Neurol. 2022. | | 1.08 | [0.98; 1.19] | 0.13 | 0.0099 | 0.0996 | 67% |
| Omitting Dhar et al. Ann Indian Acad Neurol. 2022. | | 1.08 | [0.98; 1.17] | 0.10 | 0.0087 | 0.0934 | 64% |
| Omitting Gerschenfeld et al. Eur Stroke J. 2022. | | 1.07 | [0.97; 1.17] | 0.17 | 0.0079 | 0.0889 | 64% |
| Omitting Hendrix et al. J Neurointerv Surg. 2022. | | 1.09 | [0.99; 1.20] | 0.08 | 0.0100 | 0.0998 | 66% |
| Omitting Li et al. Stroke Vasc Neurol. 2022. (0.1mg/kg) | | 1.09 | [0.99; 1.20] | 0.08 | 0.0100 | 0.0999 | 66% |
| Omitting Li et al. Stroke Vasc Neurol. 2022. (0.25mg/kg) | | 1.09 | [0.98; 1.20] | 0.10 | 0.0112 | 0.1056 | 67% |
| Omitting Li et al. Stroke Vasc Neurol. 2022. (0.32mg/kg) | | 1.09 | [0.99; 1.20] | 0.08 | 0.0100 | 0.0999 | 66% |
| Omitting Menon et al. Lancet. 2022. | | 1.09 | [0.98; 1.21] | 0.10 | 0.0122 | 0.1104 | 65% |
| Omitting Teivane et al. Medicina (Kaunas). 2022. | | 1.07 | [0.98; 1.17] | 0.12 | 0.0081 | 0.0901 | 64% |
| Omitting Tsivgoulis et al. Ann Neurol. 2022. | | 1.07 | [0.97; 1.18] | 0.16 | 0.0095 | 0.0973 | 66% |
| Omitting George et al. J Clin Neurosci. 2021. | | 1.08 | [0.98; 1.20] | 0.11 | 0.0114 | 0.1070 | 67% |
| Omitting Psychogios et al. Thera Adv Neurol Disord. 2021. | | 1.08 | [0.98; 1.19] | 0.11 | 0.0099 | 0.0996 | 67% |
| Omitting Sundar et al. Neurol Asia. 2019. | | 1.10 | [1.01; 1.19] | 0.03 | 0.0053 | 0.0727 | 62% |
| Omitting Campbell et al. N Engl J Med. 2018. | | 1.07 | [0.97; 1.18] | 0.14 | 0.0095 | 0.0972 | 66% |
| Omitting Parsons et al. N Engl J Med. 2012. | | 1.07 | [0.98; 1.18] | 0.12 | 0.0086 | 0.0929 | 65% |
| **Random effects model** | | **1.08** | **[0.99; 1.19]** | **0.09** | **0.0095** | **0.0976** | **65%** |

```
        0.1  0.2   0.5   1    2    5   10
            Higher in ALT  Higher in TNK
```

mRS 0 to 1

| Study | mRS 0 to 1 | RR | 95%-CI | P-value | Tau2 | Tau | I2 |
|---|---|---|---|---|---|---|---|
| Omitting Chandra et al. Arch Med Health Sci. 2023. | | 1.07 | [1.00; 1.16] | 0.06 | 0.0045 | 0.0673 | 45% |
| Omitting Wang et al. Lancet. 2023. | | 1.07 | [0.99; 1.17] | 0.10 | 0.0061 | 0.0782 | 45% |
| Omitting Warach et al. JAMA Neurol. 2023. | | 1.05 | [1.00; 1.11] | 0.07 | < 0.0001 | 0.0008 | 8% |
| Omitting Bivard et al. Lancet Neurol. 2022. | | 1.08 | [1.00; 1.16] | 0.05 | 0.0044 | 0.0663 | 46% |
| Omitting Estella et al. J Pers Med. 2022. | | 1.09 | [1.02; 1.16] | 0.02 | 0.0039 | 0.0624 | 39% |
| Omitting Kvistad et al. Lancet Neurol. 2022. | | 1.10 | [1.04; 1.16] | < 0.01 | 0.0027 | 0.0521 | 21% |
| Omitting Li et al. Stroke Vasc Neurol. 2022. (0.1mg/kg) | | 1.08 | [1.01; 1.17] | 0.03 | 0.0041 | 0.0642 | 44% |
| Omitting Li et al. Stroke Vasc Neurol. 2022. (0.25mg/kg) | | 1.08 | [1.00; 1.16] | 0.05 | 0.0045 | 0.0674 | 46% |
| Omitting Li et al. Stroke Vasc Neurol. 2022. (0.32mg/kg) | | 1.08 | [1.00; 1.17] | 0.05 | 0.0045 | 0.0669 | 45% |
| Omitting Menon et al. Lancet. 2022. | | 1.08 | [0.99; 1.17] | 0.07 | 0.0054 | 0.0737 | 45% |
| Omitting Tsivgoulis et al. Ann Neurol. 2022. | | 1.08 | [1.00; 1.16] | 0.06 | 0.0050 | 0.0707 | 46% |
| Omitting Campbell et al. N Engl J Med. 2018. | | 1.07 | [0.99; 1.16] | 0.07 | 0.0047 | 0.0684 | 45% |
| Omitting Logallo et al. Lancet Neurol. 2017. | | 1.09 | [1.00; 1.18] | 0.05 | 0.0049 | 0.0700 | 40% |
| Omitting Huang et al. Lancet Neurol. 2015. | | 1.08 | [1.00; 1.16] | 0.05 | 0.0044 | 0.0664 | 46% |
| Omitting Parsons et al. N Engl J Med. 2012. (0.1 mg/kg) | | 1.07 | [1.00; 1.16] | 0.06 | 0.0045 | 0.0668 | 45% |
| Omitting Haley et al. Stroke. 2010. (0.1mg/kg) | | 1.08 | [1.00; 1.16] | 0.05 | 0.0044 | 0.0663 | 46% |
| Omitting Haley et al. Stroke. 2010. (0.25mg/kg) | | 1.08 | [1.00; 1.16] | 0.05 | 0.0044 | 0.0666 | 46% |
| Omitting Haley et al. Stroke. 2010. (0.4mg/kg) | | 1.08 | [1.00; 1.16] | 0.04 | 0.0043 | 0.0653 | 45% |
| Omitting Parsons et al. Neurology. 2009. | | 1.07 | [1.00; 1.15] | 0.05 | 0.0044 | 0.0664 | 42% |
| **Random effects model** | | **1.08** | **[1.00; 1.16]** | **0.04** | **0.0043** | **0.0655** | **43%** |

```
        0.1  0.2   0.5   1    2    5   10
            Higher in ALT  Higher in TNK
```

**Supplementary Figure 8.** Cumulative meta-analyses and leave-one-out influence analyses. mRS, modified Rankin Scale; RR, risk ratio; CI, confidence interval; TNK, tenecteplase; ALT, alteplase.

Complete recanalization

| Study | Complete Recanalization | RR | 95%-CI | P-value | Tau2 | Tau | I2 |
|---|---|---|---|---|---|---|---|
| Omitting Checkouri et al. Eur Stroke J. 2023. | | 1.26 | [0.90; 1.77] | 0.16 | 0.1436 | 0.3789 | 69% |
| Omitting Mohan et al. Ann Indian Acad Neurol. 2023. | | 1.18 | [0.80; 1.74] | 0.37 | 0.2638 | 0.5136 | 79% |
| Omitting Walton et al. Ann Pharmacother. 2023. | | 1.21 | [0.81; 1.82] | 0.33 | 0.2615 | 0.5114 | 78% |
| Omitting Zhao et al. Front Neurol. 2023. | | 1.08 | [0.72; 1.62] | 0.69 | 0.2492 | 0.4992 | 73% |
| Omitting Bivard et al. Lancet Neurol. 2022. | | 1.17 | [0.76; 1.79] | 0.45 | 0.3033 | 0.5507 | 79% |
| Omitting Gerschenfeld et al. Eur Stroke J. 2022. | | 1.18 | [0.77; 1.81] | 0.43 | 0.3006 | 0.5483 | 79% |
| Omitting Hendrix et al. J Neurointerv Surg. 2022. | | 1.09 | [0.73; 1.64] | 0.64 | 0.2598 | 0.5097 | 78% |
| Omitting Menon et al. Lancet. 2022. | | 1.15 | [0.75; 1.77] | 0.50 | 0.3044 | 0.5517 | 79% |
| Omitting George et al. J Clin Neurosci. 2021. | | 1.18 | [0.81; 1.72] | 0.37 | 0.2629 | 0.5128 | 78% |
| Omitting Psychogios et al. Thera Adv Neurol Disord. 2021. | | 1.12 | [0.74; 1.70] | 0.57 | 0.2802 | 0.5293 | 79% |
| Omitting Sundar et al. Neurol Asia. 2019. | | 1.12 | [0.75; 1.68] | 0.54 | 0.2676 | 0.5173 | 79% |
| Omitting Campbell et al. N Engl J Med. 2018. | | 1.12 | [0.74; 1.71] | 0.57 | 0.2862 | 0.5350 | 79% |
| Omitting Huang et al. Lancet Neurol. 2015. | | 1.18 | [0.77; 1.81] | 0.41 | 0.2925 | 0.5408 | 79% |
| Omitting Parsons et al. N Engl J Med. 2012. (0.1 mg/kg) | | 1.11 | [0.73; 1.69] | 0.60 | 0.2808 | 0.5299 | 78% |
| Omitting Parsons et al. Neurology. 2009. | | 1.06 | [0.73; 1.54] | 0.73 | 0.2135 | 0.4620 | 75% |
| **Random effects model** | | 1.15 | [0.78; 1.69] | 0.46 | 0.2668 | 0.5165 | 78% |

0.1  0.2  0.5  1  2  5  10
Higher in ALT   Higher in TNK

Mortality

| Study | Mortality | RR | 95%-CI | P-value | Tau2 | Tau | I2 |
|---|---|---|---|---|---|---|---|
| Omitting Chandra et al. Arch Med Health Sci. 2023. | | 0.95 | [0.81; 1.12] | 0.54 | 0.0728 | 0.2698 | 61% |
| Omitting Mohan et al. Ann Indian Acad Neurol. 2023. | | 0.97 | [0.82; 1.14] | 0.68 | 0.0718 | 0.2679 | 61% |
| Omitting Murphy et al. Ann Emerg Med. 2023. | | 0.97 | [0.81; 1.15] | 0.71 | 0.0803 | 0.2835 | 57% |
| Omitting Qureshi et al. J Stroke Cerebrovasc Dis. 2023. (No Thrombectomy) | | 0.94 | [0.80; 1.12] | 0.51 | 0.0780 | 0.2794 | 61% |
| Omitting Qureshi et al. J Stroke Cerebrovasc Dis. 2023. (Thrombectomy) | | 0.95 | [0.80; 1.13] | 0.58 | 0.0805 | 0.2838 | 61% |
| Omitting Sjogren et al. IBRO Neurosci Rep. 2023. | | 0.94 | [0.80; 1.10] | 0.42 | 0.0656 | 0.2561 | 59% |
| Omitting Walton et al. Ann Pharmacother. 2023. | | 0.96 | [0.81; 1.14] | 0.62 | 0.0747 | 0.2733 | 61% |
| Omitting Wang et al. Lancet. 2023. | | 0.94 | [0.80; 1.12] | 0.49 | 0.0742 | 0.2723 | 61% |
| Omitting Warach et al. JAMA Neurol. 2023. | | 0.93 | [0.79; 1.10] | 0.39 | 0.0638 | 0.2525 | 47% |
| Omitting Zhao et al. Front Neurol. 2023. | | 0.95 | [0.81; 1.12] | 0.53 | 0.0724 | 0.2691 | 61% |
| Omitting Bivard et al. Lancet Neurol. 2022. | | 0.96 | [0.81; 1.14] | 0.62 | 0.0742 | 0.2724 | 61% |
| Omitting Dhar et al. Ann Indian Acad Neurol. 2022. | | 0.95 | [0.80; 1.12] | 0.51 | 0.0716 | 0.2676 | 61% |
| Omitting Estella et al. J Pers Med. 2022. | | 0.96 | [0.81; 1.13] | 0.59 | 0.0748 | 0.2735 | 61% |
| Omitting Gerschenfeld et al. Eur Stroke J. 2022. | | 0.97 | [0.82; 1.15] | 0.74 | 0.0756 | 0.2749 | 60% |
| Omitting Kvistad et al. Lancet Neurol. 2022. | | 0.94 | [0.81; 1.10] | 0.41 | 0.0646 | 0.2542 | 59% |
| Omitting Li et al. Stroke Vasc Neurol. 2022. (0.1mg/kg) | | 0.96 | [0.81; 1.13] | 0.61 | 0.0746 | 0.2732 | 61% |
| Omitting Li et al. Stroke Vasc Neurol. 2022. (0.25mg/kg) | | 0.97 | [0.82; 1.14] | 0.68 | 0.0710 | 0.2664 | 60% |
| Omitting Li et al. Stroke Vasc Neurol. 2022. (0.32mg/kg) | | 0.96 | [0.81; 1.14] | 0.64 | 0.0742 | 0.2724 | 61% |
| Omitting Menon et al. Lancet. 2022. | | 0.96 | [0.80; 1.14] | 0.60 | 0.0826 | 0.2874 | 61% |
| Omitting Tsivgoulis et al. Ann Neurol. 2022. | | 1.01 | [0.87; 1.17] | 0.89 | 0.0368 | 0.1918 | 51% |
| Omitting Warach et al. Stroke. 2022. | | 0.98 | [0.83; 1.15] | 0.79 | 0.0689 | 0.2626 | 60% |
| Omitting George et al. J Clin Neurosci. 2021. | | 0.96 | [0.82; 1.14] | 0.66 | 0.0719 | 0.2681 | 61% |
| Omitting Mahawish et al. Stroke. 2021. | | 0.98 | [0.83; 1.15] | 0.78 | 0.0709 | 0.2662 | 60% |
| Omitting Psychogios et al. Thera Adv Neurol Disord. 2021. | | 0.96 | [0.82; 1.14] | 0.65 | 0.0729 | 0.2700 | 61% |
| Omitting Zhong et al. Stroke. 2021. | | 0.95 | [0.80; 1.12] | 0.52 | 0.0763 | 0.2761 | 61% |
| Omitting Campbell et al. N Engl J Med. 2018. | | 0.98 | [0.83; 1.15] | 0.76 | 0.0697 | 0.2640 | 60% |
| Omitting Logallo et al. Lancet Neurol. 2017. | | 0.95 | [0.80; 1.13] | 0.56 | 0.0778 | 0.2789 | 61% |
| Omitting Huang et al. Lancet Neurol. 2015. | | 0.95 | [0.81; 1.13] | 0.56 | 0.0741 | 0.2723 | 61% |
| Omitting Parsons et al. N Engl J Med. 2012. (0.1 mg/kg) | | 0.96 | [0.81; 1.14] | 0.65 | 0.0732 | 0.2706 | 61% |
| Omitting Haley et al. Stroke. 2010. (0.1mg/kg) | | 0.97 | [0.83; 1.14] | 0.72 | 0.0694 | 0.2635 | 60% |
| Omitting Haley et al. Stroke. 2010. (0.25mg/kg) | | 0.96 | [0.81; 1.14] | 0.63 | 0.0753 | 0.2744 | 61% |
| Omitting Haley et al. Stroke. 2010. (0.4mg/kg) | | 0.97 | [0.82; 1.14] | 0.67 | 0.0731 | 0.2703 | 61% |
| **Random effects model** | | 0.96 | [0.81; 1.13] | 0.61 | 0.0723 | 0.2688 | 60% |

0.1  0.2  0.5  1  2  5  10
Higher in ALT   Higher in TNK

**Supplementary Figure 8.** Cumulative meta-analyses and leave-one-out influence analyses. RR, risk ratio; CI, confidence interval; TNK, tenecteplase; ALT, alteplase.

JoS

Koh et al.    Tenecteplase Versus Alteplase in Acute Ischemic Stroke

sICH

| Study | sICH | RR | 95%-CI | P-value | Tau2 | Tau | I2 |
|---|---|---|---|---|---|---|---|
| Omitting Chandra et al. Arch Med Health Sci. 2023. | | 0.94 | [0.73; 1.21] | 0.61 | 0.0888 | 0.2979 | 24% |
| Omitting Mohan et al. Ann Indian Acad Neurol. 2023. | | 0.94 | [0.73; 1.21] | 0.62 | 0.0889 | 0.2982 | 24% |
| Omitting Sjogren et al. IBRO Neurosci Rep. 2023. | | 0.90 | [0.71; 1.15] | 0.39 | 0.0783 | 0.2799 | 19% |
| Omitting Walton et al. Ann Pharmacother. 2023. | | 0.94 | [0.73; 1.21] | 0.63 | 0.0917 | 0.3028 | 25% |
| Omitting Wang et al. Lancet. 2023. | | 0.91 | [0.70; 1.19] | 0.50 | 0.0981 | 0.3132 | 22% |
| Omitting Warach et al. JAMA Neurol. 2023. | | 1.03 | [0.83; 1.29] | 0.77 | 0 | 0 | 0% |
| Omitting Zhao et al. Front Neurol. 2023. | | 0.92 | [0.72; 1.18] | 0.51 | 0.0867 | 0.2944 | 24% |
| Omitting Bivard et al. Lancet Neurol. 2022. | | 0.93 | [0.73; 1.19] | 0.56 | 0.0871 | 0.2951 | 23% |
| Omitting Dhar et al. Ann Indian Acad Neurol. 2022. | | 0.92 | [0.72; 1.17] | 0.48 | 0.0847 | 0.2910 | 22% |
| Omitting Estella et al. J Pers Med. 2022. | | 0.88 | [0.69; 1.12] | 0.29 | 0.0670 | 0.2588 | 16% |
| Omitting Gerschenfeld et al. Eur Stroke J. 2022. | | 0.96 | [0.74; 1.24] | 0.73 | 0.0975 | 0.3122 | 25% |
| Omitting Hendrix et al. J Neurointerv Surg. 2022. | | 0.92 | [0.72; 1.17] | 0.48 | 0.0844 | 0.2906 | 22% |
| Omitting Kvistad et al. Lancet Neurol. 2022. | | 0.90 | [0.71; 1.15] | 0.39 | 0.0791 | 0.2812 | 17% |
| Omitting Li et al. Stroke Vasc Neurol. 2022. (0.1mg/kg) | | 0.92 | [0.72; 1.18] | 0.49 | 0.0851 | 0.2918 | 23% |
| Omitting Li et al. Stroke Vasc Neurol. 2022. (0.25mg/kg) | | 0.94 | [0.73; 1.21] | 0.60 | 0.0887 | 0.2979 | 25% |
| Omitting Li et al. Stroke Vasc Neurol. 2022. (0.32mg/kg) | | 0.92 | [0.72; 1.19] | 0.53 | 0.0871 | 0.2951 | 24% |
| Omitting Menon et al. Lancet. 2022. | | 0.92 | [0.71; 1.21] | 0.55 | 0.1015 | 0.3186 | 23% |
| Omitting Tsivgoulis et al. Ann Neurol. 2022. | | 0.94 | [0.73; 1.22] | 0.64 | 0.0935 | 0.3058 | 25% |
| Omitting Warach et al. Stroke. 2022. | | 0.95 | [0.74; 1.23] | 0.69 | 0.0937 | 0.3061 | 24% |
| Omitting George et al. J Clin Neurosci. 2021. | | 0.95 | [0.74; 1.23] | 0.71 | 0.0932 | 0.3054 | 24% |
| Omitting Hall et al. Stroke. 2021. | | 0.95 | [0.74; 1.21] | 0.65 | 0.0893 | 0.2989 | 23% |
| Omitting Mahawish et al. Stroke. 2021. | | 0.96 | [0.75; 1.24] | 0.76 | 0.0911 | 0.3019 | 23% |
| Omitting Psychogios et al. Thera Adv Neurol Disord. 2021. | | 0.91 | [0.71; 1.16] | 0.42 | 0.0814 | 0.2853 | 20% |
| Omitting Zhong et al. Stroke. 2021. | | 0.94 | [0.73; 1.22] | 0.65 | 0.0930 | 0.3050 | 25% |
| Omitting Sundar et al. Neurol Asia. 2019. | | 0.93 | [0.72; 1.21] | 0.59 | 0.0920 | 0.3033 | 25% |
| Omitting Campbell et al. N Engl J Med. 2018. | | 0.93 | [0.72; 1.20] | 0.57 | 0.0884 | 0.2973 | 25% |
| Omitting Logallo et al. Lancet Neurol. 2017. | | 0.92 | [0.71; 1.19] | 0.52 | 0.0951 | 0.3083 | 24% |
| Omitting Huang et al. Lancet Neurol. 2015. | | 0.94 | [0.73; 1.21] | 0.61 | 0.0924 | 0.3039 | 25% |
| Omitting Parsons et al. N Engl J Med. 2012. (0.1 mg/kg) | | 0.95 | [0.74; 1.22] | 0.68 | 0.0895 | 0.2992 | 23% |
| Omitting Haley et al. Stroke. 2010. (0.1mg/kg) | | 0.94 | [0.73; 1.21] | 0.61 | 0.0887 | 0.2979 | 24% |
| Omitting Haley et al. Stroke. 2010. (0.25mg/kg) | | 0.92 | [0.72; 1.19] | 0.52 | 0.0870 | 0.2950 | 24% |
| Omitting Haley et al. Stroke. 2010. (0.4mg/kg) | | 0.91 | [0.71; 1.16] | 0.44 | 0.0820 | 0.2864 | 20% |
| **Random effects model** | | **0.93** | **[0.73; 1.19]** | **0.56** | **0.0871** | **0.2951** | **23%** |

0.1   0.2   0.5   1   2   5   10
Higher in ALT    Higher in TNK

Any ICH

| | Any ICH | RR | 95%-CI | P-value | Tau2 | Tau | I2 |
|---|---|---|---|---|---|---|---|
| Mohan et al. Ann Indian Acad Neurol. 2023. | | 1.03 | [0.89; 1.20] | 0.66 | < 0.0001 | 0.0011 | 32% |
| Murphy et al. Ann Emerg Med. 2023. | | 0.99 | [0.84; 1.17] | 0.92 | < 0.0001 | 0.0008 | 33% |
| Sjogren et al. IBRO Neurosci Rep. 2023. | | 1.02 | [0.87; 1.18] | 0.84 | < 0.0001 | 0.0013 | 35% |
| Walton et al. Ann Pharmacother. 2023. | | 1.02 | [0.87; 1.19] | 0.79 | < 0.0001 | 0.0002 | 36% |
| Wang et al. Lancet. 2023. | | 1.04 | [0.89; 1.23] | 0.60 | 0.0015 | 0.0393 | 34% |
| Zhao et al. Front Neurol. 2023. | | 1.01 | [0.87; 1.17] | 0.88 | < 0.0001 | 0.0019 | 29% |
| Dhar et al. Ann Indian Acad Neurol. 2022. | | 1.01 | [0.87; 1.18] | 0.84 | < 0.0001 | 0.0021 | 31% |
| Kvistad et al. Lancet Neurol. 2022. | | 1.00 | [0.88; 1.14] | 1.00 | < 0.0001 | 0.0023 | 12% |
| Li et al. Stroke Vasc Neurol. 2022. (0.1mg/kg) | | 1.02 | [0.88; 1.18] | 0.81 | < 0.0001 | 0.0005 | 32% |
| Li et al. Stroke Vasc Neurol. 2022. (0.25mg/kg) | | 1.02 | [0.88; 1.19] | 0.75 | < 0.0001 | 0.0013 | 36% |
| Li et al. Stroke Vasc Neurol. 2022. (0.32mg/kg) | | 1.02 | [0.88; 1.18] | 0.81 | < 0.0001 | 0.0005 | 32% |
| Menon et al. Lancet. 2022. | | 1.07 | [0.89; 1.28] | 0.46 | < 0.0001 | 0.0003 | 33% |
| George et al. J Clin Neurosci. 2021. | | 1.04 | [0.89; 1.20] | 0.62 | < 0.0001 | 0.0026 | 30% |
| Hall et al. Stroke. 2021. | | 1.04 | [0.89; 1.21] | 0.62 | < 0.0001 | 0.0016 | 33% |
| Psychogios et al. Thera Adv Neurol Disord. 2021. | | 1.02 | [0.88; 1.18] | 0.81 | < 0.0001 | 0.0019 | 31% |
| Sundar et al. Neurol Asia. 2019. | | 1.03 | [0.89; 1.20] | 0.69 | < 0.0001 | 0.0011 | 34% |
| Logallo et al. Lancet Neurol. 2017. | | 1.04 | [0.88; 1.23] | 0.65 | 0.0029 | 0.0540 | 35% |
| Huang et al. Lancet Neurol. 2015. | | 1.04 | [0.89; 1.20] | 0.62 | < 0.0001 | 0.0013 | 31% |
| Haley et al. Stroke. 2010. (0.1mg/kg) | | 1.03 | [0.88; 1.20] | 0.71 | < 0.0001 | 0.0017 | 34% |
| Haley et al. Stroke. 2010. (0.25mg/kg) | | 1.03 | [0.88; 1.20] | 0.73 | < 0.0001 | 0.0016 | 35% |
| Haley et al. Stroke. 2010. (0.4mg/kg) | | 1.02 | [0.88; 1.19] | 0.80 | < 0.0001 | 0.0008 | 34% |
| effects model | | **1.02** | **[0.88; 1.19]** | **0.74** | **< 0.0001** | **0.0012** | **32%** |

0.1   0.2   0.5   1   2   5   10
Higher in ALT    Higher in TNK

**Supplementary Figure 8.** Cumulative meta-analyses and leave-one-out influence analyses. sICH, symptomatic intracranial hemorrhage; ICH, intracranial hemorrhage; RR, risk ratio; CI, confidence interval; TNK, tenecteplase; ALT, alteplase.

Early neurological improvement



Parenchymal hemorrhage



**Supplementary Figure 8.** Cumulative meta-analyses and leave-one-out influence analyses. RR, risk ratio; CI, confidence interval; TNK, tenecteplase; ALT, alteplase.